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Are case reports at all relevant and useful? A case report of an unusual case of mesothelioma prompts a discussion
and concludes that they do have a role but that their observations and conclusions need to be treated with care.
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personal practice of individual doctors the rare unusual
experiences often loom larger and influence our behav-
iour more perhaps than they ought. The bleed in an
anti-coagulated patient is more vividly remembered than
the unseen patients whose thromboembolic stroke has
been prevented [2]. Nevertheless case reports of striking
and unusual clinical cases, such as this one, are the
bread and butter of many medical journals and it is per-
haps worth considering the purposes they serve. In the era
of evidence based healthcare when the randomised trial
appears to be the ultimate arbiter of good practice, do they
still earn their page space and PubMed citations?
Clearly for very rare conditions they do, as they may
be the only source of evidence to guide patient manage-
ment. For instance adult pulmonary blastoma has gener-
ated 20 or so case report PubMed citations in the past
10 years and the cumulated experience reported in them,
and summarised in a handful of reviews, may help guide
an uncertain clinical team - though even that function
may now be superseded by online discussion forums and
their more immediate feedback. But case reports of rare
presentations or very unusual clinical manifestations of
more common conditions are perhaps less helpful.* Correspondence: tom.treasure@gmail.com
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article, unless otherwise stated.The report published in this journal [1] of an unusual
patient with malignant pleural mesothelioma (MPM)
with long term disease control following surgery alone is
a case in point. Is it of mere passing interest or does it
help us understand the condition and its management?
The authors describe a single case with an uncharacter-
istic pattern of disease and their two conclusions that
the long survival observed could be either attributed to
‘margin-free tumor resection’ or to the fact that some
subgroups have ‘lower malignant potential, leading to
improved survival’ are entirely reasonable.
In patients with a typical MPM having radical surgery,
the tumour always crosses the resection margin [3]. This
presentation as a localised (albeit large) chest wall tumour
is the exception; the characteristic disease along the vis-
ceral pleura was not present in this patient. For virtually
all patients with mesothelioma the term ‘macroscopic
complete resection’ is misleading. The definition of
complete resection is histological. Look under the
microscope and there is always disease up to the resec-
tion margin – but not in this case. It is the quite excep-
tional behaviour of the cancer in this instance which
makes it worth reporting. It is a nice example of ‘the ex-
ception proves the rule’. That there is an exception does
not undermine the generality of the rule.1
We know only too well that all cancers, including meso-
thelioma are variable in their clinical behaviour and al-
though histopathological examination (and now genomic
testing) can provide clinically useful sub-classification, it isd Central Ltd. This is an Open Access article distributed under the terms of the
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the ‘gold standard’, histopathological diagnosis has never-
theless plenty of instances of exception and continues to
be a negotiated ‘framing’ of the disease [4]. The ‘frame’ is
shifted to accommodate new groupings and subdivisions.
Histopathological diagnoses are not God-given and im-
mutable but resolved by human committees.
So this case report does not really help us manage bet-
ter the great majority of patients with mesothelioma. But
it does remind us that each patient is unique and some-
times we need to consider a unique approach. In clinical
surgery there are plenty of circumstances where the sur-
geon and patient agree a ‘one-off ’ surgical plan and so
they should. General rules are applied with judgement to
reach an individualised decision. Good quality observa-
tional studies and data analyses based on them are often
sufficient to provide the rule. That applies when there is
a clear mechanistic and temporal relationship between
the intervention and benefit. Common examples in thor-
acic surgery are the relief of tension pneumothorax,
draining pus from an empyema, or retrieving an inhaled
object from the airway. When there is long time course,
variability in the cancer biology, and multiple treatments
are used in sequence or in parallel, as in mesothelioma,
it may require a randomised trial, so difficult to do in
surgery [5], to clinch the argument [6]. MARS is widely
accepted as putting EPP beyond reasonable practice in
all but an exceptional case such as this. Even then the
principle reason for survival may be that there was a
‘lower malignant potential’ as the authors suggest, rather
than the surgery itself.
In summary, case reports are written and published
when there is something exceptional to write up. In this
instance it is a rare exception that merits publication and
it indicates the existence of a general rule. Read with inter-
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